银发经济或成下一个风口(共8份)
银发经济或成下一个风口
-
艾媒咨询|2021Q1中国保健品及NMN市场研究报告
本报告研究涉及企业/品牌/案例:汤臣倍健,健合集团,同仁堂,雅本化学,金达威
iiMedia Research (艾媒咨询)数据显示,随着国家人均GDP的提升,消费者在保健食品消费理念和消费意愿上都发生了根本性的转变,保健食品在消费属性上将逐渐从可选消费品向必选消费品转变,预计2021年中国保健品市场规模将增至2708亿元。在新冠疫情影响下,国民保健意识加速觉醒,居民消费观念升级,对保健品需求增加,为保健品行业带来长期利好。此外,市场对抗衰老产品需求的提升推动了NMN成分产品的走俏,预计到2023年将会以近70.25%的增速攀升至270.13亿元。
As the data of iiMedia Research showed, with the increase of the country's per capita GDP, consumers' consumption concept and willingness of health food have undergone fundamental changes. The consumption attribute of health food will gradually change from optional consumer goods to compulsory consumer goods. It is estimated that the market scale of health food in China will increase to 270.8 billion yuan in 2021. Under the influence of COVID-19, the awareness of national health care has been speeded up, the consumption concept of residents has been upgraded, and the demand for health products has increased, which has brought long-term benefits to the health care products industry. In addition, the increasing demand for anti-aging products in the market has promoted the popularity of NMN products, which is expected to rise to 27.013 billion yuan with a growth rate of nearly 70.25% by 2023. -
艾媒咨询|2020年第三季度中国中药材行业数据监测季度报告
本报告研究涉及企业/品牌/案例:同仁堂、香雪制药、白云山。
数据显示,2020年第三季度,中药材价格指数迎来上涨周期。艾媒咨询分析师认为,受动物类等少数品种拉动影响,预计2020年10-11月中药材指数会持续走高,但是在12月维稳。据调查,绝大多数商户将会在2021年密切关注行业相关政策、谨慎经营,采取减少压货炒作等经营方式。因而,预计中药材市场在2020年末旺季会有一波行情的走高,但随着旺季结束,明年年初的价格会重新回落,随着疫情的常态化,中药材市场行情预期会呈周期性波动的态势。
Data show that in the third quarter of 2020, Chinese Herbal Medicine Price Index ushered in an upward cycle. iiMedia Research believe that by a small number of animals and other species pull the impact of October 2020-november Chinese herbal medicine index is expected to continue to rise, but stable in December. According to the survey, the vast majority of businesses in the 2021 will pay close attention to industry-related policies, prudent management, to reduce speculation and other business practices. As a result, the Chinese herbal medicine market is expected to see a wave of rising prices in the peak season at the end of 2020. However, as the peak season ends, prices will fall back early next year, and as the epidemic becomes more normal, chinese medicinal materials market is expected to be cyclical fluctuations in the situation. -
艾媒报告|2019-2020中国保健品行业研究报告
本报告研究涉及企业/品牌/案例:无限极,汤臣倍健,康宝莱,Swisse;其他提及企业/品牌:安利,东阿阿胶,合生元,完美,同仁堂,新时代健康,惠氏
iiMedia Research (艾媒咨询)数据显示,过去6年保健品行业市场规模保持两位数的增速,至2019年,市场规模约达2227亿元,2021年有望突破3300亿元。随着健康消费观念提升,养生需求从“银发一族”逐渐往“年轻一代”扩散。此外新兴科技与行业融合将推动产品和服务升级,为行业发展带来利好。消费者方面,超四成的受访者将产品品牌作为其购买时首要考虑因素,其中43.8%的消费者是自发购买保健品的,另外消费者对保健品行业的信心逐渐恢复,五成受访者看好保健品行业发展,超七成受访消费者认为保健品行业合规性有所提高。艾媒咨询分析师认为,目前保健品行业呈较好发展态势,但与此同时保健品行业同质化竞争激烈,在消费人群的扩大化、细分化的趋势下,企业需要通过加强品牌建设和精细化管理,提升产品及服务品质,更好适应市场变化。
According to the data of iiMedia Research,in the past 6 years, the market size of the health products industry has maintained a double-digit growth rate. By 2019, the market size will be approximately 222.7 billion yuan, which is expected to exceed 330 billion yuan in 2021. With the upgrading concept of healthy consumption, the demand for health care has gradually spread from the “silver-haired people” to the “younger generation”. In addition, the integration of emerging technologies and industries will promote the improving of products and services, bringing benefits to the development of the industry. In terms of consumers, over 40% of the interviewees regard product brand as their primary consideration when purchasing. 43.8% of consumers purchase health products spontaneously. In addition, consumer confidence in the health care product industry has gradually recovered. Nearly 50% of the respondents are optimistic about the development of the health care product industry, and over 70% of the consumers believe that the compliance of the health care product industry has improved. Besides, consumer confidence in the health care product industry has gradually recovered. Nearly 50% of the respondents are optimistic about the development of the health care product industry, and over 70% of the interviewed consumers believe that the compliance of the health care product industry has improved. iiMedia Consulting analysts believe that the current health care industry is showing a good development trend, but at the same time, under the trend of expanding and subdividing consumer groups ,the homogenization of the health care industry is fiercely competitive. Enterprises need to enhance the quality of products and services by strengthening brand building and refined management to better adapt to market changes. -
艾媒报告|2020年中国后疫时代医疗防护行业及细分领域分析报告
本报告研究涉及企业/品牌/案例:欣龙控股,振德医疗,奥美医疗,尚荣医疗,际华集团,蓝帆医疗,兵装集团;其他提及企业/品牌:金三发科技,中国石油,赢合科技,鑫台铭,斯凯瑞,CM朝美,华东医药,爱马斯,海王星辰,北京同仁堂,拼多多,天猫,京东,上海通用五菱,比亚迪,龙头股份,华纺股份,水星家纺,红豆股份
2020年4月3日,全球知名的新经济产业第三方数据挖掘和分析机构iiMedia Research(艾媒咨询) 发布《2020年中国后疫时代医疗防护行业及细分领域分析报告》。报告根据艾媒数据中心、艾媒咨询商业情报数据库、艾媒商情舆情数据监测系统基础数据,对2020年中国医疗防护行业及其细分领域的口罩、防护服、手套、护目镜等进行分析。此外,报告探讨产业上下游的运营模式,结合对欣龙控股、振德医疗、奥美医疗、尚荣医疗、际华集团、蓝帆医疗和兵装集团等典型企业的案例分析,对钢铁行业总体运行情况进行分析,并结合新冠疫情对2020-2021年中国医疗防护产业发展进行趋势预判。相较于发达国家,中国的医疗防护行业起步晚,防护水平低,由于医疗防护用品属于低值耗材,所以国内市场的品牌化理念也不强。但是,随着近些年中国经济的发展,国内的医疗防护市场逐渐升温,新老企业都有了品牌意识。在未来的发展道路上,品牌化和专业化将成为国内医疗防护用品生产企业的核心竞争力。
The outbreak of new crown pneumonia has raised awareness of personal protection, and the market potential for medical protective supplies is huge, and China's demand for medical protective equipment such as masks and gloves is expected to grow rapidly. In addition, the global outbreak of the new crown has also become a great opportunity for the export of China's medical protection products. As the first region to erupt in the outbreak, China has the first advantage of medical protective supplies, and the production capacity of medical protective supplies can be exported overseas. -
艾媒报告|2019-2021年中国中药材用户调研及延伸市场研究报告
本报告研究涉及企业/品牌/案例:同仁堂,片仔癀,东阿阿胶,太极集团,胡庆余堂,同仁牛黄清心丸,黄芪颗粒,雷氏丹参片,云峰气血口服液,太极五子衍宗丸,太极生力雄丸,仲景左归丸,一笑堂龟甲壳,白云山复方丹参片,天士力养血清脑颗粒,白云山夏桑菊颗粒,白云山板蓝根颗粒
随着居民消费水平的提升和健康保健意识的增强,总体健康需求在扩大,进而推动中医药市场的发展,2018年中国中药材市场规模达1246亿元,同比增长22.40%,预计到2024年,中药材市场规模将达2004亿元。
iiMedia Research(艾媒咨询)调查显示,2019年接近五成受访者购买过中药材,滋补养生和治病是购买中药材的两大目的。由于中医药应用范围广泛,中医药产业链不断扩展延伸,并加速扩展和整合。同仁堂、片仔癀、东阿阿胶等中药巨头企业纷纷布局中药材后市场,建设中药大健康产业,如植物提取物、保健食品、中药化妆品等,已成为我国生命健康产业中最具成长性的组成部分。
According to the iiMedia Research survey, nearly 50% of respondents have bought Chinese herbal medicines in 2019, and tonic sage and cure are the two main purposes for buying Chinese herbal medicines. Due to the wide range of applications of Chinese medicine, the Chinese medicine industry chain continues to expand and expand and accelerate the expansion and integration. Tongrentang, tablets, Dong'a gum and other Chinese medicine giant enterprises have laid out the chinese medicine after the market, the construction of chinese medicine large health industry, such as plant extracts, health food, Chinese medicine cosmetics, etc., has become China's life and health industry in the most growth component.
(以下为节选页,完整版共88页) -
艾媒报告|2019-2021年中国中药材行业发展现状及产业链分析报告
本报告研究涉及企业/品牌/案例:白云山,同仁堂,云南白药,昆明制药,华润三九,天士力,央视财经,牛黄,薏仁,茯苓,黄芪,川芎,片仔癀,中国中药,紫鑫药业,九洲药业,陇神戎发,众生药业,通化金马,江中药业,寿仙谷,新天药业,盘龙药业,佛慈制药,昆药集团,香雪制药,六味地黄丸,人参养荣丸,四神丸,白蚀丸,血脂康胶囊,茵栀黄口服液,一捻金胶囊,乙肝益气解郁颗粒,二十七味定坤丸,十六味冬青丸,参芪消渴胶囊,十香返生丸,华润三九,红日药业,源和药业,太龙药业,中智药业,培力控股,盛实百草,芍花堂,亳药千草,汇群中药
国内经济增长以及居民消费水平的提高都刺激着中药医疗消费需求的增长。iiMedia Research(艾媒咨询)调查显示,有49%的受访用户倾向中医药治疗,与西药基本持平。2018年中国中药材市场规模达1246亿元,同比增长22.40%,在巨大的需求驱动下,中药材种植面积扩大,药材产量将会持续增长。
中药材主要包括上游种植、养殖市场,中游流通市场和下游销售市场三大环节。目前,中药饮片和中成药生产是中药产业的核心,主要包括中药加工,包括中药配方颗粒、中药饮片加工、中成药制造等。中药饮片领域方面,行业销售收入增速分别在2016和2018年触底回升,华润三九、中国中药、红日药业等上市公司表现良好;中药配方颗粒方面,2006-2016年,中国市场销售额占饮片市场销售额比重由1.2%增加至6.0%,中药配方颗粒或将成为中药饮片加工行业应用广泛的产品;中成药方面,随着国家医改政策的推行,中成药消费需求趋于合理,中成药产量开始回落,但仍处于一个比较高的产量水平,云南白药、白云山、同仁堂、紫鑫药业等上市企业表现良好。
Chinese medicinal materials mainly include upstream planting, breeding market, midstream circulation market and downstream sales market three links. At present, the production of Chinese medicine tablets and traditional Chinese medicine is the core of the Chinese medicine industry, including the processing of Traditional Chinese medicine, including Chinese medicine formula particles, Chinese medicine tablet processing, traditional Chinese medicine manufacturing. In the field of Chinese medicine tablets, the growth rate of sales revenue in the industry rebounded in 2016 and 2018, respectively, china Resources 39, Chinese medicine, Red Day Pharmaceuticals and other listed companies performed well; Chinese medicine formula particles may become a widely used product in the Chinese medicine tablet processing industry, Chinese medicine, with the implementation of the national medical reform policy, the consumption demand of traditional Chinese medicine tends to be reasonable, the production of Traditional Chinese medicine began to fall, but still at a relatively high level of production, Yunnan White Medicine, Baiyunshan, Tongrentang, Zixin Pharmaceutical and other listed enterprises performed well. -
艾媒报告 |2019全球与中国养老金融行业现状及发展前景分析报告
本报告研究涉及企业/品牌/案例:新华保险,中国人寿,太平洋人寿,平安养老,新华人寿,太平养老,太平人寿,泰康养老,泰康人寿,阳光人寿,中信保诚,中意人寿,应答人寿,同仁堂,汤臣倍健,九州通,云南白药,国寿养老,华夏资金,工银瑞信,南方基金,渣打银行,宏利保险,建设银行,兴业银行,广发银行,天弘基金,光大银行,中信银行,招商银行,安邦保险
2018年,中国60岁以上老年人占总人口的16.1%,意味着中国已经进入深度老龄化社会,特别是养老金融成为了解决中国深度老龄化社会面临的关键问题。目前,中国养老金融体系与发达国家相比仍有较大差距,美国的商业养老保险占比35.2%,规模达到9.9万亿美元,而中国第一大支柱为基本养老保险制度,占到整个养老体系近80%,规模仅4.4万亿元。同时,由于中国的第一支柱基本养老保险替代率和第二支柱年金覆盖率低,超过8成中国国民未达资产储备预期,仅依靠第一和第二支柱无法满足当前的养老保障形势;而第三支柱在快速识别和及时响应消费者个性需求方面独具优势,基础需求旺盛。iiMedia Research(艾媒咨询)数据显示,现阶段中国公民养老投资偏好最大的依然是银行存款或银行理财占30.2%,然后是商业养老保险产品(20.5%)、股票基金(13.2%)以及购买房产(10.0%)。艾媒咨询分析师认为,近年来互联网和移动支付的普及,大大提高了中老年人获取金融服务的便利性;基于大数据和人工智能分析的金融科技的持续进步,提升了养老金投资科学性和专业性,成为推动养老服务金融快速发展的重要动力;特别是随着服务型政府的建设推进、PPP融资模式的进一步发展,中国养老金融市场发展将更加完善。
In 2018, China's elderly (60 years & above) accounted for 16.1% of the total population, which means that China has entered an aging society. Pension finance has become a key factor in solving China's deep aging society. At present, China's pension financial system still has a big gap compared with developed countries. The commercial pension insurance in US accounts for 35.2% of the total, and its scale reaches 9.9 trillion dollars. However, the first pillar of pension finance in China is the basic pension insurance system, which accounts for nearly 80% of the entire pension system, with a scale of only 4.4 trillion yuan. At the same time, due to the low replacement rate of China’s first pillar of pension finance and the low coverage rate of the second pillar, more than 80% of Chinese nationals fail to meet their demand; The third pillar of pension finance in China has unique advantages in quickly identifying and responding to consumers' needs in a timely manner, and its basic needs are strong. According to data from iiMedia Research, the biggest preference for Chinese citizens is bank deposits and bank wealth management, which account for 30.2%, followed by commercial pension insurance products (20.5%), equity funds (13.2%), and purchase of real estate. (10.0%). iiMedia Consulting analysts believe that the popularity of Internet and mobile payment in recent years has greatly improved the convenience of accessing financial services for middle-aged and elderly people; the continuous improvement of financial technology based on big data and artificial intelligence analysis improves the science of pension investment. Financial technology becomes an important driving force for the rapid development of pension service finance in China. With the development of service-oriented government and PPP financing model, China's pension market will be further improved.
- 1
- 2
- 3
- 4
没找到想要的报告?
扫码添加客服参与预约/定制,第一时间获取行业推荐报告!
智库热榜
艾媒咨询|2024-2025年中国银发经济投资前景分析报告
艾媒咨询|2024-2025年中国烘焙食品行业现状及趋势研究报告
艾媒咨询 | 2023-2024年中国休闲食品产业现状及消费行为数据研究报告
艾媒咨询|2024-2025年全球及中国新能源汽车行业消费趋势监测与案例研究报告
艾媒咨询 | 2023-2024年中国全域旅游产业运行数据及发展趋势研究报告
艾媒咨询 | 2024年中国家用美容仪行业消费者洞察研究报告
艾媒咨询|赵一鸣零食店消费行为洞察及行业趋势报告(2024)
艾媒咨询|2024年中国月饼行业创新发展研究报告
艾媒咨询 | 2024年中国数字中台市场研究报告
艾媒咨询|2023-2024年全球及中国跨境电商运营数据及典型企业分析研究报告
艾媒咨询|2024年中国家清产品消费趋势洞察报告